Meletios A. Dimopoulos, MD

Articles by Meletios A. Dimopoulos, MD

Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis

September 24th 2026

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

ByMeletios A. Dimopoulos, MD

September 23rd 2026

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

Meletios A. Dimopoulos, MD, on the Future of a Combination Therapy in Multiple Myeloma

ByMeletios A. Dimopoulos, MD

June 26th 2020

Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma

ByMeletios A. Dimopoulos, MD

June 8th 2020

Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.